Menu
Not yet recruiting NCT07116356

Molecular Characterization of Carbapenemase-Producing Enterobacterales

No phase Interventional Acute Myeloid Leukemia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Antibiotic administration, Molecular detection of antibiotic resistance.
Who it may be relevant to
Registry conditions: Acute Myeloid Leukemia. Basic parameters: 4 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Molecular Characterization of Carbapenemase-Producing Enterobacterales Isolated From Clinical Samples in Egypt

Overview

Bacterial infections with carbapenem resistant pathogens are one of the major threats in immunocompromised patients, especially among cancer patients .Furthermore, Gram negative pathogens are becoming increasingly prevalent and have become an ongoing global health concern .Emergence of Gram-negative pathogens, especially Enterobacterales that avert many of the human defense mechanisms are alarmingly increasing and most of these pathogens are resistant to many of the in-use antibiotics including carbapenems .

Interventions

  • Diagnostic test Antibiotic administration
    different samples were collected from patients admitted at oncology center at sohag
  • Diagnostic test Molecular detection of antibiotic resistance
    Molecular detection of carbapenem resistant genes: * Extraction of nucleic acid from isolated organisms by boiling. * Primers will be used for detection of carbaenem resistant genes

Primary outcome measures

  • Isolation of causative organism [Time frame: 6 months]
Secondary outcome measures (2)
  • Antibitic sensitivity test: [Time frame: 2 months]
  • Molecular detection of carbapenem resistant genes: [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

  • All patients admitted to Sohag Oncology Center have different infections and isolated organism one of carbapenem resistant enterobacterales detected by antibiotic sensitivity test.

Exclusion criteria

  • All patients admitted to Sohag Oncology Center having infections in different sites and isolated organisms are not one of enterobacterales and not carbapenem resistant.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Triple blind
Primary purpose
Screening

Study locations

Egypt · 1 center
  • Sohag university, Faculty of medicine — Sohag

Identifiers

NCT: NCT07116356 · Soh-Mmed-25-7-10PD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗